HOME >> BIOLOGY >> NEWS
Candidate hookworm vaccine shows benefits in animal study

A paper published in this week's PLoS Medicine shows that vaccination against a protein secreted by the dog hookworm can protect against blood loss and anaemia caused by the same hookworm in dogs. The researchers, led by Alex Loukas and Peter Hotez, showed that vaccination of dogs with recombinant Ac-APR-1, an enzyme that starts the digestion of hemoglobin in hookworms, induced an immune response and resulted in significantly reduced hookworm burdens and fecal egg counts in vaccinated dogs compared to control dogs after challenge with infective larvae of the hookworm Ancylostoma caninum. Most importantly, vaccinated dogs were protected against blood loss and most did not develop anemia, the major result of hookworm disease.

Hookworms are intestinal parasites of mammals, including humans, dogs, and cats; in humans these infections are a leading cause of intestinal blood loss and iron-deficiency anemia. Hookworm infections occur mostly in tropical and subtropical climates and are estimated to infect about 1 billion people worldwide-- about one-fifth of the world's population. People who have direct contact with soil that contains human feces in areas where hookworm is common are at high risk of infection; because children play in dirt, they are at the highest risk.

These results set the stage for the next stage of vaccine development in humans. Loukas and colleagues suggest that the ideal hookworm vaccine would be a mixture of two recombinant proteins, targeting both the infective larva and the blood-feeding adult stage (as targeted here) of the parasite. Such a vaccine would limit the amount of blood loss caused by feeding worms and maintain normal levels of hemoglobin.


'"/>

Contact: Paul Ocampo
press@plos.org
415-624-1224
Public Library of Science
3-Oct-2005


Page: 1

Related biology news :

1. Candidate research sites selected for the National Ecological Observatory Network
2. Designed peptides: Candidates for the treatment of cancer, sexual dysfunction, eating disorders
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Handicapping tuberculosis may be the way to a better vaccine
6. Developing a more effective vaccine for tuberculosis
7. New target for HIV/AIDS drugs and vaccine discovered
8. Genomic analysis uncovers new targets for HIV vaccine
9. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
10. Universal flu vaccine being tested on humans
11. From clinical cancer research: rethinking therapeutic cancer vaccine trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
Cached News: